• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. reiterated coverage on Turning Point with a new price target

    4/6/21 6:07:01 AM ET
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPTX alert in real time by email
    HC Wainwright & Co. reiterated coverage of Turning Point with a rating of Buy and set a new price target of $186.00 from $190.00 previously
    Get the next $TPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPTX

    DatePrice TargetRatingAnalyst
    5/20/2022$58.00Buy
    BofA Securities
    3/1/2022$50.00 → $45.00Hold
    Stifel
    2/10/2022$120.00 → $85.00Overweight
    Wells Fargo
    1/21/2022$115.00 → $105.00Outperform
    Oppenheimer
    12/7/2021Outperform
    Cowen & Co.
    11/10/2021$150.00 → $115.00Outperform
    Oppenheimer
    10/12/2021$178.00 → $162.00Buy
    HC Wainwright & Co.
    10/11/2021Market Outperform → Market Perform
    JMP Securities
    More analyst ratings

    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Nicholson Garry A (tax withholding)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:43:52 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Machado Patrick (withholding obligation)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:41:51 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: George Simeon returned $171,278,160 worth of shares to the company (2,253,660 units at $76.00) to cover taxes

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:40:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Turning Point Therapeutics Inc.

      15-12G - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/29/22 4:30:18 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Turning Point Therapeutics Inc.

      EFFECT - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/23/22 12:15:10 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:25 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TPTX
    Financials

    Live finance-specific insights

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

      Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

      7/27/22 6:59:00 AM ET
      $BMY
      $IMTX
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

      Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

      5/5/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

      In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

      4/12/22 4:46:10 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

      SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

      5/16/22 8:30:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

      SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

      3/29/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Turning Point Therapeutics Inc.

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 3:02:35 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 2:35:02 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/9/22 10:01:27 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Turning Point Therapeutics with a new price target

      BofA Securities initiated coverage of Turning Point Therapeutics with a rating of Buy and set a new price target of $58.00

      5/20/22 7:27:32 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Turning Point with a new price target

      Stifel reiterated coverage of Turning Point with a rating of Hold and set a new price target of $45.00 from $50.00 previously

      3/1/22 11:13:37 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo reiterated coverage on Turning Point with a new price target

      Wells Fargo reiterated coverage of Turning Point with a rating of Overweight and set a new price target of $85.00 from $120.00 previously

      2/10/22 7:06:48 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care